Metffil VG 1mg/500mg/0.2mg Tablet SR contains a combination of Glimepiride 1mg, Metformin 500mg and Voglibose 0.2mg in sustained-release tablet form. It belongs to the ANTI DIABETIC category and is manufactured and marketed by Fourrts India Laboratories Pvt Ltd.
Composition
- Glimepiride: 1mg
- Metformin: 500mg
- Voglibose: 0.2mg
Product Information
- Product Name: Metffil VG 1mg/500mg/0.2mg Tablet SR
- Generic: Glimepiride 1mg + Metformin 500mg + Voglibose 0.2mg
- Dosage Form: Sustained-Release Tablet
- Manufacturer: Fourrts India Laboratories Pvt Ltd
- Marketer: Fourrts India Laboratories Pvt Ltd
- Category: ANTI DIABETIC
About Glimepiride, Metformin and Voglibose
Glimepiride is a sulfonylurea antidiabetic medicine that helps lower blood glucose by stimulating the pancreas to release insulin.
Metformin is an oral antidiabetic medicine that helps reduce blood glucose levels, primarily by decreasing glucose production in the liver and improving insulin sensitivity.
Voglibose is an alpha-glucosidase inhibitor that helps control the rise in blood glucose after meals by slowing the digestion and absorption of carbohydrates.
Usage Information
Use Metffil VG 1mg/500mg/0.2mg Tablet SR only as directed by your doctor or healthcare professional. Swallow the sustained-release tablet as instructed and follow the prescribed dosage and schedule.
For complete product information, including dosage, storage instructions, precautions, contraindications, and expiry details, refer to the original packaging before use.
